Characterization of copy number variations (CNV) patterns and pseudotime trajectories in high-grade serous ovarian cancer (HGSOC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...
Reva Medical, LLC announced the presentation of results from a subgroup analysis of the MOTIV BTK pivotal trial for the ...
At VIVA 2026, the Vascular InterVentional Advances conference, William A. Gray, MD, presented findings from a subgroup analysis ...
HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a ...
Of 882 participants enrolled, 128 had PD-L1 CPS < 1 and 373 had CPS 1-19. For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 ...
The values of the subgroup-variable, which is specified in the chart statement, indicate how the observations in the input data set (a DATA=, HISTORY=, or TABLE= data set) are arranged into rational ...
Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results